AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

RecruitingNAAges 40 Years - 85 YearsAllOregon Health and Science University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017) * age 40-85 at time of screening * ability to understand and cooperate with simple instructions in English * ability to read at 6th grade reading level in English * ability to stand unassisted for at least 30 seconds and to be able walk independently with a walker * ability to refrain from new physical and speech therapy programs for the duration of the study * ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic sedative or NMDA receptor antagonists for the duration of the study * females of child-bearing age must perform a urine pregnancy test and be on reliable birth control during the course of the study Exclusion Criteria: * other significant neurological or vestibular disorders * presence of electrically, magnetically or mechanically activated implants or history of injurious metal exposure in eyes, head, or body
๐Ÿ’Š

What it tests

  • Repetitive transcranial magnetic stimulation (rTMS)
๐Ÿ“

Where

1 site
Oregon Health & Science University
Portland, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy